Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.35 |
| ▸ | JAK2 | O60674 | 6/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 4/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379002 | 0.98 | HCRTR1 (0.34) | JAK3JAK2OPRD1CHEK2PDCD1 | |
| SCHEMBL2378512 | 0.93 | DPP4 (0.33) | JAK3JAK2OPRD1DPP4JAK1 | |
| SCHEMBL2378019 | 0.92 | CHEK2 (0.35) | JAK3JAK2CHEK2JAK1HCRTR1 | |
| SCHEMBL2379368 | 0.91 | HCRTR1 (0.34) | JAK3JAK2OPRD1DPP4JAK1 | |
| SCHEMBL2379014 | 0.90 | OPRD1 (0.41) | OPRD1CHEK2 | |
| SCHEMBL2377584 | 0.90 | CHEK2 (0.36) | JAK3JAK2CHEK2DGAT1 | |
| SCHEMBL2378288 | 0.88 | PRMT5 (0.40) | OPRD1CHEK2 | |
| SCHEMBL2378996 | 0.87 | JAK2 (0.37) | JAK3JAK2JAK1NAMPT | |
| SCHEMBL2377749 | 0.87 | JAK2 (0.37) | JAK3JAK2JAK1DGAT1 | |
| SCHEMBL2377819 | 0.86 | JAK2 (0.42) | JAK3JAK2CHEK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | JAK3 2/4885JAK2 5/4885OPRD1 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.